Latest filing published 27 Aug 2010 for Sarepta Therapeutics, Inc., €8,382.
Insider track record
No signal scores available.
Closed purchases
Based on 2 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- -42.4%Entry US$12.60 · Close at T+365 US$7.26
- +77.9%Entry US$4.08 · Close at T+365 US$7.26
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
J. David Boyle II: trading record in brief
J. David Boyle II discloses dealings in 2 companies, chiefly Sarepta Therapeutics, Inc. and XOMA Royalty Corp. We count 5 filings; the first trade dates from 15 March 2006 and the latest from 27 August 2010.
Purchases make up the whole of the open-market record (2 purchases, €18k). A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 3 share grants. So far in 2010, the count stands at 1 purchase and no sales.
Most recently, on 27 August 2010, the filings show an open-market purchase worth €8,382 in Sarepta Therapeutics, Inc. Most trades are made public on the day they happen. Section 16 rules allow two business days to file each Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to J. David Boyle II
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 5,000 shares@ US$2.13Common StockSEC:0000873303-10-000064:0Canonical exit: 25 Nov 2010 (T+90)
- 19,000 shares@ US$0.6392Common StockSEC:0001257957-09-000019:0Canonical exit: 11 Jun 2009 (T+90)
- 46,282 shares0Common StockSEC:0001257957-09-000014:0
- 5,195 shares@ US$3.19Common SharesSEC:0001221231-07-000005:0
- 8,739 shares@ US$1.69Common SharesSEC:0001221231-06-000009:0
5 of 5 declarations
